Format

Send to

Choose Destination
ACS Med Chem Lett. 2014 Feb 8;5(4):416-21. doi: 10.1021/ml4005232. eCollection 2014 Apr 10.

Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.

Author information

1
Department of Medicinal Chemistry, Department of Bioscience, and Department of Physical and Metabolic Sciences, AstraZeneca R&D Charnwood , Bakewell Road, Loughborough, Leicestershire LE11 5RH, U.K.

Abstract

A series of dibasic des-hydroxy β2 receptor agonists has been prepared and evaluated for potential as inhaled ultralong acting bronchodilators. Determination of activities at the human β-adrenoreceptors demonstrated a series of highly potent and selective β2 receptor agonists that were progressed to further study in a guinea pig histamine-induced bronchoconstriction model. Following further assessment by onset studies in guinea pig tracheal rings and human bronchial rings contracted with methacholine (guinea pigs) or carbachol (humans), duration of action studies in guinea pigs after intratracheal (i.t.) administration and further selectivity and safety profiling AZD3199 was shown to have an excellent over all profile and was progressed into clinical evaluation as a new ultralong acting inhaled β2 receptor agonist with rapid onset of action.

KEYWORDS:

AZD3199; COPD; adrenoreceptor agonist; asthma; inhaled; uLABA; β2 receptor agonist

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center